Treating protozoal-retroviral co-infections, especially Leishmania-HIV co-infections, using mono- or disubstituted quinoline derivatives

摘要

The use of mono- or disubstituted quinolines (I) for treating protozoal-retroviral co-infections is new. The use of mono- or disubstituted quinolines of formula (I) or their salts is claimed in the preparation of a medicament for treating protozoal-retroviral co-infections. R1 = H, 1-15C alkyl, 2-15C alkenyl, 2-15C alkynyl, CHO or heteroaryl (optionally substituted by one or more OH), 1-15C alkyl or 2-15C alkenyl substituted by one or more of O, halo, OH, CHO, COOH, aryloxycarbonyl, 2-8C alkoxycarbonyl, 3-9C alkenyloxycarbonyl, CN, NH2, 1-7C alkoxy, 3-6C cycloalkyl, aryl, heteroaryl, heteroaryloxy, arylsulfonyl, 1-7C alkylsulfonyl, 1-7C thioalkyl or 1-7C aminoalkyl; 2-7C alkynyl substituted by one or more of O, halo, OH, CHO, COOH, aryloxycarbonyl, 2-8C alkoxycarbonyl, 3-9C alkenyloxycarbonyl, CN, aryl, heteroaryl, arylsulfonyl, 1-7C alkylsulfonyl, 1-7C thioalkyl or 1-7C aminoalkyl or 2-15C alkylene (sic) or alkynyl substituted by tri-(1-7C alkyl)-silyl; R2 (in the 3-, 6- or 8-position) = H, halo, OH, CHO, COOH, 1-7C alkyl, 1-7C alkoxy, NH2, 2-7C alkenyl (optionally substituted by one or more 1-7C alkoxy) or 2-10C alkynyl (optionally substituted by heteroaryl); provided that R1 and R2 are not both H. Independent claims are included for compounds (I') and their salts for use as medicaments and pharamceutical compositions containing (I') or their salts, where (I') have formula (I) in which: R1 = 1-7C alkyl or 2-7C alkenyl (both optionally substituted by one or more of OH, NH2, aryl, 1-4C alkoxy or 1-4C aminoalkyl), and R2 (in the 3-, 6- or 8-position) = 3-7C alkenyl substituted by one or more 1-7C alkoxy; or 2-10C alkynyl (optionally substituted by heteroaryl), or R1 = H, CHO, heteroaryl (optionally substituted by one or more OH) or 8-15C alkyl, 1-15C alkyl substituted by one or more of O, halo, OH, CHO, COOH, aryloxycarbonyl, 2-8C alkoxycarbonyl, 3-9C alkenyloxycarbonyl, CN, OPh, 3-6C cycloalkyl, aryl, heteroaryloxy, arylsulfonyl, 1-7C alkylsulfonyl or 1-7C thioalkyl, 1-7C alkyl substituted by one or more of 5-7C alkoxy and 5-7C aminoalkyl, 6-15C alkyl substituted by heteroaryl, 8-15C alkyl substituted by one or more of OH, NH2, 1-7C alkoxy and 1-7C aminoalkyl, 8-15C alkenyl, 2-7C alkenyl substituted by one or more of O, halo, OH, CHO, COOH, aryloxycarbonyl, 2-8C alkoxycarbonyl, 3-9C alkenyloxycarbonyl, CN, OPh, 3-6C cycloalkyl, heteroaryloxy, arylsulfonyl, 1-7C alkylsulfonyl, 1-7C thioalkyl, 5-7C alkoxy or 1-7C aminoalkyl, 3-7C alkenyl substituted by heteroaryl, 2-15C alkynyl, 2-7C alkynyl substituted by one or more of O, halo, OH, CHO, COOH, aryloxycarbonyl, 2-8C alkoxycarbonyl, 3-9C alkenyloxycarbonyl, CN, aryl, heteroaryl, arylsulfonyl, 1-7C alkylsulfonyl, 1-7C thioalkyl or 1-7C aminoalkyl; or 2-15C alkylene (sic) or alkynyl substituted by one or more tri-(1-7C alkyl)-silyl; and R2(in the 3-, 6- or 8-position) = H, halo, OH, CHO, COOH, 1-7C alkyl, 1-7C alkoxy, NH2, 2-7C alkenyl (optionally substituted by one or more 1-7C alkoxy) or 2-10C alkynyl (optionally substituted by heteroaryl).